Title:
【発明の名称】PSKH-1リボザイムおよび疾患治療におけるその使用
Document Type and Number:
Japanese Patent JP2002515726
Kind Code:
A
Abstract:
Disclosed is a purified full-length cDNA molecule encoding putative serine kinase enzyme (PSKH-1), and the expression of the cDNA in a recombinant host cell to produce substantially purified PSKH-1, per se. Inactivation of PSKH-1 pre-MRNA or PSKH-1 mRNA halts DNA synthesis and cell division. Also disclosed are ribozymes capable of cleaving PSKH-1 pre-mRNA or mRNA and thus deactivating PSKH-1 translation. Ribozymes of the hammerhead and hairpin motifs, and various compositions containing same, are also disclosed. The ribozymes compositions are used in the treatment of mammalian patients suffering from diseases or medical conditions characterized by abnormal cell proliferation or growth such as cancer and various non-malignant diseases or medical conditions such as autoimmune diseases, allograft rejection and atherosclerosis.
Inventors:
Pritz Hans Peter Blankenborg
Brade Gaute
Brade Gaute
Application Number:
JP51261497A
Publication Date:
May 28, 2002
Filing Date:
September 18, 1996
Export Citation:
Assignee:
Pritz Hans Peter Blankenborg
Brade Gaute
Brade Gaute
International Classes:
A61K31/7105; A61K48/00; A61P9/10; A61P37/06; C12N5/10; C12N9/00; C12N9/12; C12N15/09; C12N15/113; A61K38/00; (IPC1-7): C12N15/09; A61K31/7105; A61K48/00; A61P9/10; A61P37/06; C12N5/10; C12N9/00
Attorney, Agent or Firm:
Kinichi Kitamura (3 others)
Previous Patent: カポジ肉腫および腹膜後繊維腫症に関連するガンマヘルペスウイルスのＤ...
Next Patent: ロドコッカス スピーシーズＩＧＴＳ８によるＤＢＴの脱硫におけるＤｓ...
Next Patent: ロドコッカス スピーシーズＩＧＴＳ８によるＤＢＴの脱硫におけるＤｓ...